All 2026 dates on sale. Register before December 31!
The neurotoxin market is segmenting by duration, offering providers options from 2-3 weeks to 6 months for personalized patient care. January 2026 also brought Level 1 evidence for neck rejuvenation, clinical data on regenerative approaches, and FDA clearances expanding aesthetic devices into medical applications.
January 2026 brought major GLP-1 updates, from the launch of the first oral Wegovy pill to a new federal insurance model that contrasts sharply with growing state-level restrictions. This roundup synthesizes the key clinical and regulatory news, providing practice-focused takeaways on what providers need to know about the evolving landscape.
Is weight regain inevitable after you stop taking GLP‑1 drugs like Ozempic or Wegovy? This article explains why most people regain, what the “keep it off” group does differently, and how holistic programs like Clean Start Weight Loss® can help you plan for life beyond injections.
Discover 5 hidden GLP-1 side effects linked to malnutrition—from chills to hair loss. Learn warning signs, timelines, and why comprehensive lifestyle support is essential for safe weight loss.
Treating platysma bands with neurotoxins represents a significant opportunity for aesthetic practitioners to differentiate their expertise beyond traditional facial injections. However, mastering this advanced neck rejuvenation technique requires comprehensive training in complex anatomy, risk management, and patient selection to ensure safe, effective outcomes.
October 2025 brought major regulatory and clinical updates shaping aesthetic medicine—from the FDA’s RF microneedling alert to new neurotoxin and device approvals. These developments highlight how evidence-based innovation and patient education are redefining safe, inclusive, and profitable practice growth.
The World Health Organization’s endorsement of GLP-1 therapies for obesity treatment adds significant global validation to what providers already know: medical weight management continues to evolve with new clinical data, expanded treatment options, and refined care models. This update summarizes the four most clinically relevant developments shaping your practice and patient outcomes.
The FDA has approved the first oral GLP-1 pill for weight loss, delivering comparable efficacy to injectable formulations while addressing patient concerns about needles and cost. For aesthetic medicine practitioners, understanding this new GLP-1 treatment option is essential for informed patient conversations about weight management.
The WHO’s endorsement of GLP-1s for obesity marks a pivotal moment in medical weight management. Discover strategies to differentiate your practice and thrive in this evolving landscape.
The World Health Organization’s endorsement of GLP-1 therapies for obesity treatment adds significant global validation to what providers already know: medical weight management continues to evolve with new clinical data, expanded treatment options, and refined care models. This update summarizes the four most clinically relevant developments shaping your practice and patient outcomes.
Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!